Immunotherapy:a promising therapy for anaplastic thyroid carcinoma

Abstract:

Anaplastic thyroid carcinoma (ATC) is rare but one of the most aggressive human cancers, and there is no effective treatments currently. Studies of immune microenvironment in ATC suggest that immunotherapy may benefit for ATC patients, and some studies about immunotherapy in ATC have been gradually conducted. Immune checkpoint inhibitors (given alone or combined with target agents) , chimeric antigen receptor T cell (CAR-T) , and personalized tumor vaccines (PTV) were expected to be the future direction of medical therapy for ATC.